16 September 2026 editorial review · Item
Frexalimab (CD40L antagonist): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: FABULINUS protocol publication is a design paper, not efficacy. Pediatric cohort and current registry context checked; no T1D outcome upgrade.
- Registry NCT06111586: ACTIVE_NOT_RECRUITING; updated 2026-06-29; enrollment 197 (ACTUAL); primary completion 2027-04-28 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: dom.70785.